Clinical advances in hematologic malignancies: paving the way for better quality of life outcomes
F. Efficace
SESSION I: ACUTE MYELOID LEUKEMIA

Practice-changing treatments
N. Russel
Novel approaches to targeted epigenetic therapy
S. Sica
Clinical use of MRD testing
A. Venditti
Recent developments in immunotherapy
A. Isidori
SESSION II: MYELODYSPLASTIC SYNDROMES

Relevance of molecular characterization in prognostic stratification and choice of therapy
M.G. Della Porta
Targeted therapy in low risk MDS
U. Platzbecker
Novel therapies in high risk MDS
M.T. Voso
Relevance of quality of life and patient reported outcome in designing therapeutic strategies in MDS
E.N. Oliva
Transplant options in 2021
E. Angelucci
SESSION III: MYELOPROLIFERATIVE NEOPLASMS

Balancing toxicity and efficacy of JAK2 inhibitors
F. Passamonti
Unusual thrombosis
S. Siragusa
JOHN GOLDMAN LECTURE
M. Baccarani
SESSION IV: CHRONIC MYELOID LEUKEMIA

Ph+ stem cells and marrow microenvironment
S. Soverini
Patient management before and during treatment-free remission
P. Rousselot
Guidelines 2021
G. Rosti
Future perspectives of novel therapies
G. Saglio
Atypical chronic myeloid leukemia
M. Breccia
SESSION V: ACUTE LYMPHOBLASTIC LEUKEMIA

New insights in the biology of ALL
I. Iacobucci
MRD-driven strategy in Ph-like ALL: does it work?
S. Chiaretti
Current treatment strategies in T-ALL
R. Bassan
CAR- T in pediatric and adult patients
A. Biondi
SESSION VI: CHRONIC LYMPHOCYTIC LEUKEMIA

The standard of care in CLL: new guidelines
P. Ghia
Treatment with novel drugs: until progression? - No
M. Montillo
SESSION VII: NOVEL IMMUNOTHERAPIES

Bites and darts in hematological malignances: current options
C. Carlo-Stella
CAR-T in AML
L.A.E. Vago
Privacy Policy | Cookie Policy